
Accure Health enables more precise therapies by matching therapeutic designs to patients’ biomarker profiles to target the right cells for the right patients. The company operates a "Lab-in-a-Loop" platform that combines AI protein design, patented automation systems, and a proprietary biomarker database to design and validate nanobinder and nanovesicle therapeutics. Accure is a precision-medicine, B2B SaaS and biodesign provider serving biotech developers and research institutions involved in targeted therapies and clinical programs. The platform accelerates discovery and validation workflows through integrated computational design and automated lab iteration. Accure has worked with innovation incubators and national research programs to advance its biomarker-guided therapeutic pipeline.

Accure Health enables more precise therapies by matching therapeutic designs to patients’ biomarker profiles to target the right cells for the right patients. The company operates a "Lab-in-a-Loop" platform that combines AI protein design, patented automation systems, and a proprietary biomarker database to design and validate nanobinder and nanovesicle therapeutics. Accure is a precision-medicine, B2B SaaS and biodesign provider serving biotech developers and research institutions involved in targeted therapies and clinical programs. The platform accelerates discovery and validation workflows through integrated computational design and automated lab iteration. Accure has worked with innovation incubators and national research programs to advance its biomarker-guided therapeutic pipeline.
Sector: Biotechnology — precision medicine
Core offering: AI-powered Lab-in-a-Loop platform for biomarker-guided nanobinder and nanovesicle design
Founded: 2017
Headquarters: Cambridge, Massachusetts
Notable supporters: NVIDIA, Amgen, Biogen, National Cancer Institute, NIH
Precision delivery of therapeutics to specific cell types informed by biomarker profiles; accelerating discovery and validation of targeted therapies.
2017
Biotechnology
Non-equity assistance / grant funding event reported March 2024
“NVIDIA, Amgen, Biogen, National Cancer Institute, National Institutes of Health, Cherubic Ventures”